Onconova Therapeutics Stock Current Ratio
| ONTXDelisted Stock | USD 1.02 0.04 3.77% |
Onconova Therapeutics fundamentals help investors to digest information that contributes to Onconova Therapeutics' financial success or failures. It also enables traders to predict the movement of Onconova Stock. The fundamental analysis module provides a way to measure Onconova Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Onconova Therapeutics stock.
Onconova |
Onconova Therapeutics Company Current Ratio Analysis
Onconova Therapeutics' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Onconova Therapeutics Current Ratio | 7.43 X |
Most of Onconova Therapeutics' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Onconova Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
CompetitionIn accordance with the recently published financial statements, Onconova Therapeutics has a Current Ratio of 7.43 times. This is 155.33% higher than that of the Pharmaceuticals sector and 6.14% higher than that of the Health Care industry. The current ratio for all United States stocks is notably lower than that of the firm.
Onconova Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Onconova Therapeutics' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Onconova Therapeutics could also be used in its relative valuation, which is a method of valuing Onconova Therapeutics by comparing valuation metrics of similar companies.Onconova Therapeutics is currently under evaluation in current ratio category among its peers.
Onconova Fundamentals
| Return On Equity | -0.84 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (89.28) % | |||
| Current Valuation | (4.56 M) | |||
| Shares Outstanding | 21 M | |||
| Shares Owned By Insiders | 0.77 % | |||
| Shares Owned By Institutions | 7.95 % | |||
| Number Of Shares Shorted | 20.7 K | |||
| Price To Earning | (0.87) X | |||
| Price To Book | 1.43 X | |||
| Price To Sales | 92.50 X | |||
| Revenue | 226 B | |||
| Gross Profit | 226 K | |||
| EBITDA | (20.3 T) | |||
| Net Income | (18.95 T) | |||
| Cash And Equivalents | 46.53 M | |||
| Cash Per Share | 2.23 X | |||
| Debt To Equity | 1.26 % | |||
| Current Ratio | 7.43 X | |||
| Book Value Per Share | 0.69 X | |||
| Cash Flow From Operations | (17.93 T) | |||
| Short Ratio | 0.19 X | |||
| Earnings Per Share | (0.96) X | |||
| Target Price | 8.33 | |||
| Number Of Employees | 16 | |||
| Beta | 1.35 | |||
| Market Capitalization | 20.9 M | |||
| Total Asset | 22.68 T | |||
| Retained Earnings | (482.63 T) | |||
| Working Capital | 31.3 M | |||
| Current Asset | 23.18 M | |||
| Current Liabilities | 7.61 M | |||
| Z Score | -32.73 | |||
| Net Asset | 22.68 T |
About Onconova Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Onconova Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Onconova Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Onconova Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Onconova Stock
If you are still planning to invest in Onconova Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Onconova Therapeutics' history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |